EMEA-001220-PIP07-20-M01
Key facts
Invented name |
Olumiant
|
Active substance |
Baricitinib
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0364/2022
|
PIP number |
EMEA-001220-PIP07-20-M01
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019
|
Route(s) of administration |
|
Contact for public enquiries |
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|